Clinical Trials Arena May 29, 2025
Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.
A transformative application of artificial intelligence (AI) in drug development lies in its potential to match the right patient population with the right drugs, and this should be a primary focus of innovation efforts, said experts at a recent oncology-focused conference.
AI’s greatest impact could come from improving trial success rates by ensuring therapies are tested in the populations most likely to benefit, said Steve Warner, Senior Vice President and Head of Translational Research & Medicine and Oncology at Sumitomo Pharma America. Warner was speaking on a panel that delved into the impact of AI and global events on the oncology clinical trial industry at...
Today's Sponsors
Today's Sponsor